By Mill Chart
Last update: Nov 15, 2023
Take a closer look at SANOFI-ADR (NASDAQ:SNY), a remarkable value stock uncovered by our stock screener. NASDAQ:SNY excels in fundamentals and maintains a very reasonable valuation. Let's break it down further.
To assess a stock's valuation, ChartMill utilizes a Valuation Rating on a scale of 0 to 10. This comprehensive assessment considers various valuation aspects, comparing price to earnings and cash flows, while factoring in profitability and growth. NASDAQ:SNY has achieved a 8 out of 10:
ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NASDAQ:SNY, the assigned 8 is noteworthy for profitability:
ChartMill assigns a proprietary Health Rating to each stock. The score is computed by evaluating various liquidity and solvency ratios and ranges from 0 to 10. NASDAQ:SNY was assigned a score of 7 for health:
ChartMill assigns a Growth Rating to every stock. This score ranges from 0 to 10 and evaluates the different growth aspects like EPS and Revenue, both in the past as in the future. NASDAQ:SNY scores a 5 out of 10:
More Decent Value stocks can be found in our Decent Value screener.
For an up to date full fundamental analysis you can check the fundamental report of SNY
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
SANOFI-ADR
NASDAQ:SNY (4/26/2024, 7:16:56 PM)
Premarket: 49.28 +0.15 (+0.31%)49.13
-0.23 (-0.47%)
/PRNewswire/ -- Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion...
SNY earnings call for the period ending March 31, 2024.
SNY stock results show that Sanofi beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
AstraZeneca soundly topped analyst views while Sanofi narrowed its losses. Both stocks surged in early trade.
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.
Auddia stock is taking off on Monday with heavy trading of AUUD stock after the company received a new AI tech patent.
Apartment Income REIT stock is rising higher on Monday as investors in AIRC shares react to a deal to take the company private.